Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (12/01/2016)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information

Added Tawana et al. as reference 17.

Classification of Pediatric Myeloid Malignancies

Added text to state that in newly diagnosed patients with double-mutant CEPBA acute myeloid leukemia (AML), in addition to usual family history queries, germline screening should be considered, because 5% to 10% of these patients are reported to have a germline CEBPA mutation (cited Tawana et al. as reference 56).

Added text about miR-155 expression in patients with AML (cited Joyce et al., Marcucci et al., and Ramamurthy et al. as references 182, 183, and 184, respectively).

Treatment of Newly Diagnosed AML

Added text about outcomes associated with induction failure (cited Wells et al., Aplenc et al., and Quarello et al. as references 39, 40, and 41, respectively).

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Survivorship and Adverse Late Sequelae

Next section >
About This PDQ Summary